Samsung Bioepis Receives EU Bevacizumab Approval
Company Gets Fifth Biosimilar Approval By European Commision
With the European Commission’s approval of Aybintio (bevacizumab), Samsung Bioepis now has five approved biosimilars for Europe.
You may also be interested in...
Samsung Bioepis last week received a second positive opinion recommending granting a pan-European marketing authorization for a biosimilar bevacizumab product. The Korean firm spoke to Generics Bulletin detailing the rationale.
Samsung Bioepis is lining up two biosimilar bevacizumab products in the EU, after the EMA’s CHMP recommended the company’s Onbevzi product months after approval for Aybintio.
Centus Biotherapeutics has received formal European Commission approval for its Equidacent biosimilar rival to Avastin.